drugset / Trial / NCT00401479

A Study To Investigate The Effect Of Solabegron (GW427353) On Gastrointestinal Transit In Healthy Volunteers

NCT00401479

Phase 1 Completed 36 enrolled GlaxoSmithKline
RandomizedParallel-groupDouble-blindDiagnostic

Summary

This study will test the hypothesis that GW427353, a beta-3 adrenergic agonist, retards the emptying of the colon and increases total colonic transit time.

Timeline

Start
2006-10
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Solabegron Unknown